This study, which included around 6,400 patients, employed Cox regression analysis and confirmed that diabetic patients using GLP-1R agonistssuch as exenatide, liraglutide, dulaglutide, and semaglutide were less likely to receive a new glaucoma diagnosis (76)
They are used to treat inflammation (swelling)
Risks may be heightened for individuals with underlying health conditions
Regular check-ins: Schedule frequent follow-ups with your healthcare provider to assess the effectiveness of the new dosing strategy
However with adequate protein intake and strength training you can preserve this muscle mass which is important for long-term fitness, health and continued weight loss
#Semaglutide #PatentExpiry #RegulatoryAffairs #PharmaceuticalIndustry #DrugPricing #GLP1 #HealthcarePolicy yes, close to reality